Clinical Application of Autologous Mitochondria Transplantation for Improving Oocyte Quality.
Study Details
Study Description
Brief Summary
Embryo quality was ranked as one of the most important predictors in determining the success of implantation, while clinically some patients may experience repeated IVF failure due to persistent poor embryo quality.Mitochondria, as the energy factory, is confirmed being a hallmark of quality and developmental potential of human oocytes, and decreased mitochondria copy number was reported to be associated with oocyte aging and dysfunctional mitochondria would be expected to influence the late stages of oocyte maturation and early embryogenesis.The objective of this study is to evaluate the effect of mitochondria transfer from bone marrow mesenchymal stem cell on the quality of oocyte.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study is a pilot study to investigate the effect of autologous mitochondria transplantation for improving oocyte quality.
Design: randomized controlled trial. Setting: Assisted reproductive technologies unit. Patients: patients who is in accordance with the inclusion criteria, and not meet the exclusion criteria, who had repeated IVF treatment from Sep 2018 to Sep 2021.
Intervention: The comparison was made between mitochondria transfer（MIT) group and the control group, both groups are conducted with the GnRH-a super-long protocol for IVF treatment. MIT group injects autologous mitochondria from bone mesenchymal stem cells into oocyte.
Main outcome measures: The primary outcome of the study is live birth rate. The secondary outcomes were clinical pregnancy rate, number of oocytes retrieved, fertility rate, normal fertilization rate, rate of transferable embryo and good quality embryo rate.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: autologous mitochondria transplantation inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI) |
Procedure: autologous mitochondria transplantation
inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte
Combination Product: autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
autologous mitochondria transplantation
|
| Active Comparator: ICSI only has intracytoplasmic sperm injection (ICSI) |
Drug: intracytoplasmic sperm injection (ICSI)
intracytoplasmic sperm injection (ICSI)
|
Outcome Measures
Primary Outcome Measures
- live birth rate [2-3years]
number of live birth/ transferred cycle.Compare the live birth rate between the two groups with SPSS 20.0.
Secondary Outcome Measures
- clinical pregnancy rate [2-3years]
Clinical pregnancy means pregnancy sac is seen intrauterine under ultrasound 7 weeks after embryo transferred. Clinical pregnancy rate(%): number of clinical pregnancy/transferred cycle.Compare the clinical pregnancy rate between the two group with SPSS 20.0.
- number of oocytes retrieved [2-3years]
Compare the number of oocytes retrieved between the two group with SPSS 20.0.
- fertility rate [2-3years]
Fertility rate(%): number of oocyte fertilized/ number of oocytes retrieved.Compare the fertility rate between the two group with SPSS 20.0.
- normal fertility rate [2-3years]
Normal fertility rate(%): number of oocyte normally fertilized/ number of oocytes retrieved. Compare the normal fertility rate between the two group with SPSS 20.0.
- good quality embryo rate [2-3years]
Cleavage embryo grades 1 or 2 with 6-10 blastomeres were considered good quality embryos. Good quality embryo rate(%): number of good quality embryo/number of fertilized oocytes.Compare the good quality embryo rate between the two group with SPSS 20.0.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Women age >20 years and <43 years.
-
Anti-müllerian hormone（AMH） level ≥1.1 ng/ml.
-
Previous failed transfer cycle ≥2.
-
BMI>18kg/m2 and <25kg/m2.
-
Written informed consent.
Exclusion Criteria:
-
Abnormal uterine development, endometrial adhesion or previous endometrial dysplasia (<7mm)
-
Other medical diseases that cannot be pregnant.
-
Complicated with adenomyosis, endometriosis confirmed by surgery, ovarian endometriosis cyst ≥2 cm by ultrasound, all kind of malignant tumors or precancerous disease.
-
Untreated hydrosalpinx.
-
The man has definite factors that affect the quality of the embryo, such as persistent abnormal DNA fragment rate (>30%) and non-obstructive spermatozoa.
-
Intracytoplasmic sperm injection with donor.
Eliminate or falls off Criteria:
1.The number of retrieved oocytes <6.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sun Yat-sen University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- newivf20180817